Arvinas to Participate in Upcoming Investor Conferences
March 04, 2025 16:05 ET
|
Arvinas Inc.
NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Precision Neuroscience Expands Clinical Research in Brain–Computer Interface Through Collaboration with Beth Israel Deaconess Medical Center
February 27, 2025 09:00 ET
|
Precision Neuroscience
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation, a pioneering brain–computer interface (BCI) company, today announced a clinical research project with Beth Israel...
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury
February 27, 2025 08:00 ET
|
Tiziana Life Sciences Ltd.
Traumatic brain injury is a leading cause of death and disabilityCurrently, there is no treatment to prevent the long-term effects of traumatic brain injuryFindings could translate into treating...
Safetrust Secures Strategic Investment from dormakaba
February 24, 2025 13:00 ET
|
Safetrust Inc.
Safetrust secures strategic investment from dormakaba to expand access solutions, enhance security innovation, and drive post-quantum-ready advancements.
Spark Biomedical Partners With Air Force To Launch Trial Testing Innovative Solution to Motion Sickness and Spatial Disorientation
February 20, 2025 09:37 ET
|
Spark Biomedical
Dallas, TX, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Spark Biomedical, a global leader in wearable neurostimulation technology, announces an innovative study to explore the effectiveness of transcutaneous...
Neurogen Biomarking Announces Global Agreement with Quanterix for Use of Blood Biomarker Assay in its Patient-Initiated Blood Test to Support Early Detection of Dementia and Mild Cognitive Impairment Due to Alzheimer’s Disease
February 19, 2025 08:30 ET
|
Neurogen Biomarking
CHICAGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Neurogen Biomarking, the world’s first ecosystem for memory and thinking concerns announced today that they have entered into an exclusive agreement to use...
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
February 11, 2025 07:00 ET
|
Arvinas Inc.
– Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in...
Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
February 03, 2025 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
From Data to Movement: The Breakthrough Helping Paralyzed Patients Walk Again
January 16, 2025 08:00 ET
|
SciChart
From Data to Movement: NeuroRestore, powered by SciChart, combines spinal stimulation with real-time data to help paralyzed patients walk again.
From Data to Movement: The Breakthrough Helping Paralyzed Patients Walk Again
January 16, 2025 04:04 ET
|
SciChart
From Data to Movement: NeuroRestore, powered by SciChart, combines spinal stimulation with real-time data to help paralyzed patients walk again.